DALLAS, May 4, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/SNSS
Sunesis Pharmaceuticals Inc. (SNSS) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. The Company focuses primarily on the development of voreloxin for the treatment of acute myeloid leukemia (AML). It owns global development and commercialization rights to voreloxin and is preparing for the Phase III development of the compound.
Message Board Search for SNSS: http://www.boardcentral.com/boards/SNSS
In the report, the analyst notes:
"On April 19, SNSS announced that data from three Phase 2 clinical trials of voreloxin have been accepted for presentation June 7 at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, which runs from June 4 to June 8. The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer, as well as poster presentations and discussion sessions of maturing data from its two Phase 2 studies of voreloxin in AML.
"SNSS believes voreloxin represents one of the most promising anticancer compounds in development for the treatment of AML, and the outcomes of the Company's productive meetings with the FDA have provided a clear registration path for voreloxin in this indication. According to CEO Daniel Swisher, the Company is now focused on finalizing preparations for the Phase 3 trial and looks forward to sharing updated data from its fully enrolled Phase 2 AML and ovarian cancer trials at ASCO in June."
To read the entire report visit: www.microstockprofit.com/ads/SNSS
See what investors are saying about SNSS at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.